Objective It remains unclear whether the time interval between total thyroidectomy and
radioactive iodine therapy (RAIT) affects clinical outcomes in papillary thyroid carcinoma …

Objective: Postthyroidectomy radioiodine (RAI) therapy is indicated for papillary thyroid
carcinoma (PTC) with high-risk features. There is variability in the timing of RAI therapy with …

There is no consensus regarding the timing of adjuvant radioactive iodine therapy (RAI)
therapy in low-and intermediate-risk papillary thyroid carcinoma (PTC). We analyzed the …

Objective The utility of radioiodine (RAI) therapy in intermediate‐risk papillary thyroid
carcinoma (PTC) remains a topic of ongoing discussion. This systematic review and meta …

Context: Papillary thyroid cancer (PTC) is the most common endocrine malignancy. The long-
term prognosis is generally excellent. Due to a paucity of data, debate exists regarding the …

Context Current guidelines recommend a selective use of radioiodine treatment (RAI) for
papillary thyroid cancer (PTC). Objective This work aimed to determine how policy changes …

Context The optimal timing to performing thyroid surgery following a diagnosis of papillary
thyroid cancer (PTC) has yet to be fully defined. Objective We aimed to examine if a delayed …

Objective: The aim of this study was to evaluate disease-specific survival and cost related to
radioactive iodine therapy (RAI) utilization in patients with early-stage papillary thyroid …

It remains controversial whether papillary thyroid cancer (PTC) patients with low-to
intermediate-risk disease should receive radioactive iodine (RAI) after total thyroidectomy …

Objective Whether the initiating time of radioiodine (RAI) therapy will affect the clinical
outcome in differentiated thyroid cancer (DTC) remains controversial. The objective of this …